How to Source Paroxetine Oral Tablets (immediate-release) for Pharmaceutical Formulation
Paroxetine Oral Tablets (immediate-release) (Oral Tablets (immediate-release), 10 mg, 20 mg, 30 mg, 40 mg) is classified under Antipsychotropic Drugs. It is therapeutically aligned with reference brands such as US: Paxil®, Pexeva®, Brisdelle®; EU: Seroxat®, ParoMerck®, Paxetin®. This guide highlights key sourcing factors buyers should consider when procuring high-quality Paroxetine Oral Tablets (immediate-release) for formulation, R&D, or bulk manufacturing.
Product Overview:
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) that works by increasing serotonin levels in the brain to enhance mood and reduce anxiety. It is used to treat depression, panic disorder, obsessive-compulsive disorder, generalized anxiety disorder, PTSD, and social anxiety, promoting emotional stability and mental well-being.
Paroxetine immediate-release tablets are FDA-approved in the USA for depression, panic disorder, OCD...
Paroxetine Oral Tablets (immediate-release) API – ideal for compliant pharmaceutical formulation.
Quick Insight: Over 60% of formulation delays are linked to poor API sourcing. A well-planned sourcing strategy can reduce risk and accelerate market entry.
1. Regulatory Compliance & Documentation
Ensure suppliers provide:
- ✔ Valid DMF (Drug Master File)
- ✔ COA (Certificate of Analysis) for each batch
- ✔ GMP, ISO, or ICH Q7 compliance certificates
2. Purity, Grade & Specification Matching
Paroxetine Oral Tablets (immediate-release) must meet exact grade and purity for your dosage form:
- ✔ USP / EP / JP grade verification
- ✔ Particle size distribution check
- ✔ Residual solvent and heavy metal limits
3. Supplier Reliability & Audit History
- ✔ Positive past audit reports
- ✔ Pharma client references
- ✔ Years of proven API manufacturing experience
4. Commercial Terms: Pricing, MOQ & Flexibility
- ✔ Transparent pricing
- ✔ Pilot batch MOQ flexibility
- ✔ Volume-based discounts
5. Lead Time, Inventory & Logistics
Typical lead time for Paroxetine Oral Tablets (immediate-release) is 4–6 weeks.
- ✔ Emergency dispatch options
- ✔ Regional warehousing
- ✔ Special storage if needed
6. Formulation Support
- ✔ Technical datasheets
- ✔ Sample availability
- ✔ Stability study support
Pro Tip: Engage supplier formulation experts early — it can improve bioavailability and cut development time.
Conclusion
Sourcing Paroxetine Oral Tablets (immediate-release) is more than procurement—it’s a strategic partnership. With its oral tablets (immediate-release) form and 10 mg, 20 mg, 30 mg, 40 mg specification, choosing a compliant supplier ensures consistent quality and regulatory approval. Prioritize documentation, verify compatibility, and build relationships with transparent, reliable suppliers to secure long-term success.
Next Step: Get expert assistance in sourcing Paroxetine Oral Tablets (immediate-release).
Request a Quote
Frequently Asked Questions For Sourcing of Paroxetine Oral Tablets (immediate-release)
What is the typical lead time for Paroxetine Oral Tablets (immediate-release)?
Lead times range from 4–6 weeks depending on supplier and region.
Is Paroxetine Oral Tablets (immediate-release) available in multiple grades?
Yes — common grades include USP, EP, and JP. Verify grade suitability for your dosage form before purchase.
Does Paroxetine Oral Tablets (immediate-release) require special storage?
It should be stored in a cool, dry place away from direct sunlight.
Is a Drug Master File (DMF) available for Paroxetine Oral Tablets (immediate-release)?
Yes, a DMF is available for regulated markets upon request. It includes detailed quality, manufacturing, and stability data.
Can I request samples or a pilot batch of Paroxetine Oral Tablets (immediate-release)?
Yes — pilot batches or samples can be arranged for R&D, stability studies, or formulation trials. MOQ may vary based on region and regulatory scope.
What compliance certificates are available for Paroxetine Oral Tablets (immediate-release)?
Available documentation may include GMP, ISO 9001, ISO 14001, and ICH Q7 certificates, along with CoA, TDS, and stability data.
Is Paroxetine Oral Tablets (immediate-release) suitable for regulated markets like US/EU?
Yes — compliant with EU/US/WHO GMP standards and available with regulatory support documentation for filings.
Can Paroxetine Oral Tablets (immediate-release) be used in fixed-dose combinations?
Yes — many formulations support inclusion in FDCs. Compatibility studies and formulation consultation are available on request.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our
Privacy Policy.